髌股关节置换术在6年后患者报告结局的时间加权结果优于全膝关节置换术:一项随机对照试验
这项平行组等效性随机对照试验(首年设盲)纳入100例孤立性髌股关节骨关节炎患者,1:1随机接受髌股关节置换术(PFA)或全膝关节置换术(TKA)。术后6年时间加权分析显示PFA在SF-36躯体疼痛等多个患者报告结局上优于TKA,但6年时点仅SF-36活力评分组间有差异。6年翻修率与再手术率两组无显著差异,PFA组死亡率12%高于TKA组0%。
要点
- PFA组6年时间加权SF-36躯体疼痛改善35±19,优于TKA组23±17(均差12,95%CI 4-20,p=0.004)。
- 6年时点仅SF-36活力评分PFA组17±19优于TKA组8±21(均差9,95%CI 0-18,p=0.04),其他PRO无差异。
- 6年翻修率PFA组0.10(95%CI 0.04-0.20)与TKA组0.04(95%CI 0.01-0.12)无显著差异(p=0.24)。
核心结论
- PFA术后6年患者报告结局的时间加权改善优于TKA,2年时的优势在随后4年未减退。
- 仅评估6年时点则除SF-36活力外各结局工具未见一致差异,早期优势决定了6年结果。
- 本研究数据不能解释登记系统所示PFA高翻修率,作者认为PFA假体类型本身可能不存在固有问题;基于术后前6年及ROM,PFA仍是严重孤立性PF-OA的更优选择。
- PFA组6年后可能出现的高翻修率可能抵消早期优势,但只有长期研究的详细分析才能证实。
研究设计与样本
- 平行组等效性随机对照试验(首年设盲),比较PFA与TKA治疗孤立性髌股关节骨关节炎。
- 2007年至2014年间纳入100例有严重症状的PF-OA患者,1:1随机分组,每组50例。
- 6年随访前失访9%(9/100),PFA组死亡12%(6/50)、TKA组死亡0%(0/50)(p=0.02),无死亡与膝关节病情相关。
- 5次临床随访(末次在5年),术后前6年完成10套问卷,主要结局为SF-36躯体疼痛。
- 采用曲线下面积除以观察时间计算6年时间加权平均改善,竞争风险分析比较再手术与翻修率。
主要发现
- 6年时间加权SF-36躯体疼痛改善PFA组35±19 vs TKA组23±17(均差12,95%CI 4-20,p=0.004)。
- 6年时间加权SF-36躯体功能均差11(95%CI 3-18,p=0.008)、KOOS症状均差12(95%CI 5-20,p=0.002)、KOOS运动/娱乐均差8(95%CI 0-17,p=0.048)、OKS均差5(95%CI 2-8,p=0.002),均利于PFA。
- 无任何PRO维度改善利于TKA;6年时点仅SF-36活力评分PFA组17±19 vs TKA组8±21(均差9,95%CI 0-18,p=0.04)有差异,其他PRO无差异。
- 5年时ROM较基线下降PFA组-4°±14° vs TKA组-11°±13°(均差7°,95%CI 1°-13°,p=0.02),其临床重要性未知。
- 6年翻修率PFA组0.10(95%CI 0.04-0.20)vs TKA组0.04(95%CI 0.01-0.12)(p=0.24),再手术率PFA组0.10(95%CI 0.04-0.20)vs TKA组0.12(95%CI 0.05-0.23)(p=0.71),均无显著差异。
关键数值与推荐
- SF-36八个维度,范围0-100(越高越好),最小临床重要差异(MCID)6-7。
- 牛津膝关节评分(OKS)一个维度,范围0-48(越高越好),MCID 5。
- 膝关节损伤与骨关节炎结局评分(KOOS)五个维度,范围0-100(越高越好),MCID 8-10。
- 纳入标准为有严重症状的孤立性髌股关节骨关节炎患者。
- 证据等级为I级,治疗性研究。
临床怎么用
- 基于术后前6年及ROM结果,作者认为PFA仍是严重孤立性PF-OA的更优选择。
- 作者指出有必要对PFA常规使用时的初次手术及后续翻修指征提出质疑。
- 作者认为PFA假体类型本身可能不存在登记系统所提示的固有问题。
局限性
- PFA组死亡12%(6/50)与TKA组0%(0/50)存在差异(p=0.02),但无死亡与膝关节病情相关。
- 仅评估6年时点时,除SF-36活力外各结局工具未见一致差异。
- 本研究数据不能解释登记系统所示PFA高翻修率所暗示的结果快速恶化。
- PFA组6年后可能出现的高翻修率可能抵消早期优势,但只有长期研究的详细分析才能证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a previous study, we reported the 2-year outcomes of a parallel-group, equivalence, randomized controlled trial (RCT; blinded for the first year) comparing patellofemoral arthroplasty (PFA) and TKA for isolated patellofemoral osteoarthritis (PF-OA). We found advantages of PFA over TKA for ROM and various aspects of knee-related quality of life (QOL) as assessed by patient-reported outcomes (PROs). Register data show increases in PFA revision rates from 2 to 6 years after surgery at a time when annual TKA revision rates are decreasing, which suggests rapidly deteriorating knee function in patients who have undergone PFA. We intended to examine whether the early advantages of PFA over TKA have deteriorated in our RCT and whether revision rates differ between the implant types in our study after 6 years of follow-up. QUESTIONS/PURPOSES: (1) Does PRO improvement during the first 6 postoperative years differ between patients who have undergone PFA and TKA? (2) Does the PRO improvement at 3, 4, 5, and 6 years differ between patients who have undergone PFA and TKA? (3) Do patients who have undergone PFA have a better ROM after 5 years than patients who have had TKA? (4) Does PFA result in more revisions or reoperations than TKA during the first 6 postoperative years? METHODS: We considered patients who had debilitating symptoms and PF-OA as eligible for this randomized trial. Screening initially identified 204 patients as potentially eligible; 7% (15) were found not to have sufficient symptoms, 21% (43) did not have isolated PF-OA, 21% (43) declined participation, and 1% (3) were not included after the target number of 100 patients had been reached. The included 100 patients were randomized 1:1 to PFA or TKA between 2007 and 2014. Of these, 9% (9 of 100) were lost before the 6-year follow-up; there were 12% (6 of 50) and 0% (0 of 50) deaths (p = 0.02) in the PFA and TKA groups, respectively, but no deaths could be attributed to the knee condition. There were no differences in baseline parameters for patients who had PFA and TKA, such as the proportion of women in each group (78% [39 of 50] versus 76% [38 of 50]; p > 0.99), mean age (64 ± 9 years versus 65 ± 9 years; p = 0.81) or BMI (28.0 ± 4.7 kg/m 2 versus 27.8 ± 4.1 kg/m 2 ; p = 0.83). Patients were seen for five clinical follow-up visits (the latest at 5 years) and completed 10 sets of questionnaires during the first 6 postoperative years. The primary outcome was SF-36 bodily pain. Other outcomes were reoperations, revisions, ROM, and PROs (SF-36 [eight dimensions, range 0 to 100 best, minimum clinically important difference {MCID} 6 to 7], Oxford Knee Score [OKS; one dimension, range 0 to 48 best, MCID 5], and Knee Injury and Osteoarthritis Outcome Score [KOOS; five dimensions, range 0 to 100 best, MCID 8 to 10]). Average PRO improvements over the 6 years were determined by calculating the area under the curve and dividing by the observation time, thereby obtaining a time-weighted average over the entire postoperative period. PRO improvements at individual postoperative times were compared for the patients who had PFA and TKA using paired t-tests. Range of movement changes from baseline were compared using paired t-tests. Reoperation and revision rates were compared for the two randomization groups using competing risk analysis. RESULTS: Patients who underwent PFA had a larger improvement in the SF-36 bodily pain score during the first 6 years than those who underwent TKA (35 ± 19 vs. 23 ± 17; mean difference 12 [95% CI 4 to 20]; p = 0.004), and the same was true for SF-36 physical functioning (mean difference 11 [95% CI 3 to 18]; p = 0.008), KOOS Symptoms (mean difference 12 [95% CI 5 to 20]; p = 0.002), KOOS Sport/recreation (mean difference 8 [95% CI 0 to 17]; p = 0.048), and OKS (mean difference 5 [95% CI 2 to 8]; p = 0.002). No PRO dimension had an improvement in favor of TKA. At the 6-year time point, only the SF-36 vitality score differed between the groups being in favor of PFA (17 ± 19 versus 8 ± 21; mean difference 9 [95% CI 0 to 18]; p = 0.04), whereas other PRO measures did not differ between the groups. At 5 years, ROM had decreased less from baseline for patients who underwent PFA than those who had TKA (-4° ± 14° versus -11° ± 13°; mean difference 7° [95% CI 1° to 13°]; p = 0.02), but the clinical importance of this is unknown. Revision rates did not differ between patients who had PFA and TKA at 6 years with competing risk estimates of 0.10 (95% CI 0.04 to 0.20) and 0.04 (95% CI 0.01 to 0.12; p = 0.24), respectively, and also reoperation rates were no different at 0.10 (95% CI 0.04 to 0.20) and 0.12 (95% CI 0.05 to 0.23; p = 0.71), respectively. CONCLUSION: Our RCT results show that the 2-year outcomes did not deteriorate during the subsequent 4 years. Patients who underwent PFA had a better QOL throughout the postoperative years based on several of the knee-specific outcome instruments. When evaluated by the 6-year observations alone and without considering earlier observations, we found no consistent difference for any outcome instruments, although SF-36 vitality was better for patients who underwent PFA. These combined findings show that the early advantages of PFA determined the results by 6 years. Our findings cannot explain the rapid deterioration of results implied by the high revision rates observed in implant registers, and it is necessary to question indications for the primary procedure and subsequent revision when PFA is in general use. Our data do not suggest that there is an inherent problem with the PFA implant type as otherwise suggested by registries. The long-term balance of advantages will be determined by the long-term QOL, but based on the first 6 postoperative years and ROM, PFA is still the preferable option for severe isolated PF-OA. A possible high revision rate in the PFA group beyond 6 years may outweigh the early advantage of PFA, but only detailed analyses of long-term studies can confirm this. LEVEL OF EVIDENCE: Level I, therapeutic study.
引用
- Odgaard A, Kappel A, Madsen F, et al. Patellofemoral Arthroplasty Results in Better Time-weighted Patient-reported Outcomes After 6 Years than TKA: A Randomized Controlled Trial. Clin Orthop Relat Res. 2022. PMID: 35315804. doi:10.1097/CORR.0000000000002178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。